Organon & Co. (NYSE: OGN) Acquisition: Sun Pharma’s Strategic Move into Women’s Health and Biosimilars
Organon & Co. (NYSE: OGN) is set to be acquired by Sun Pharmaceutical Industries for $14.00 per share in an all-cash deal, valuing the global healthcare company at approximately $11.75 billion.
The acquisition, which sent Organon shares surging 17.01%, represents a strategic move for Sun Pharmaceutical Industries to expand its global presence, particularly in the women’s health sector and biosimilars market.
The deal faces scrutiny, with an investigation launched into Organon’s board members regarding potential undervaluation of the company.
Organon & Co. (NYSE: OGN) is a leading global healthcare company that was spun off from Merck & Co., Inc. (NYSE: MRK). It primarily focuses on women’s health by developing and delivering various health solutions. Its business also includes a robust portfolio of established brands and biosimilars, positioning it competitively among other large pharmaceutical companies.
On April 27, 2026, investment firm Piper Sandler Companies (NYSE: PIPR) upgraded Organon to a Neutral rating from its previous Underweight grade. The stock price was $13.18 at the time of the new rating. This upgrade coincides with a major announcement of a company buyout.
India’s Sun Pharmaceutical Industries agrees to acquire Organon for $14.00 per share in an all-cash deal. This news sent Organon shares surging 17.01% to $13.18. The transaction implies an enterprise value of approximately $11.75 billion for the company.
The deal is not without scrutiny. As highlighted by GlobeNewswire, the law firm Johnson Fistel has launched an investigation into Organon’s board members. The investigation questions if the board failed its duties by accepting an offer that may undervalue the company.
For Sun Pharmaceutical Industries, the acquisition is a strategic move to expand its global presence. As highlighted by Zacks, the deal helps it grow in the women’s health sector. It also provides a significant entry into the biosimilars market. The transaction is expected to close in early 2027.
